FeesSafety
Pluang+

UBS Group confirms buy rating despite narrowly missing Q3 earnings estimates.

Company Fundamentals
29 Oct 2026, 16:13 WIB
Seeking Alpha
View Source
Bullish
UBS Group confirms buy rating despite narrowly missing Q3 earnings estimates.

UBS Group's Q3 results showed strong revenue and profit, though earnings slightly missed estimates. The bank maintains a solid investment-grade rating with healthy capital ratios and manageable debt. Risks include global market volatility, equity declines, and reduced merger activity. Overall, UBS remains well-positioned with positive forward earnings growth expected.

UBS Group's Q3 results come as 96 of 142 Financials-sector US stocks tradable on Pluang rose today. For readers following Financials, here is Pluang's market snapshot as of Oct 29, 2026 19:11 WIB: HUT (Hut 8 Corp) traded at USD 67.00 with a 1-day change of -3.54% and Pluang order activity showing 59% Sell / 41% Buy; BSBR (Banco Santander Brasil SA) was priced at USD 4.70, up 3.52%, with balanced order activity; ING (ING Groep NV) stood at USD 31.77, down 3.41%, with 100% Sell orders and a typical hold time of 95 days.

More News

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...

Market News
Bullish
46 minutes ago
Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...

Company Fundamentals
Bullish
46 minutes ago
Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...

Others
Bullish
1 hour ago
Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...

Market News
Neutral
1 hour ago
Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...

Company Fundamentals
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App